Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.32 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.32 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.32 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19713582 | 1.00 | FAAH (0.34) | FAAHMGLLTUBB4ATUBBTUBA3C | |
| SCHEMBL29639612 | 0.94 | FAAH (0.36) | FAAHMGLLTUBB4ATUBBTUBA3C | |
| SCHEMBL31494777 | 0.94 | FAAH (0.36) | FAAHMGLLTUBB4ATUBBTUBA3C | |
| SCHEMBL1497619 | 0.79 | SLC9A1 (0.45) | — | |
| SCHEMBL28432280 | 0.79 | SLC9A1 (0.45) | — | |
| SCHEMBL29352246 | 0.79 | SLC9A1 (0.45) | — | |
| SCHEMBL29228763 | 0.78 | FAAH (0.32) | FAAHMGLLTUBB4ATUBBTUBA3C | |
| SCHEMBL19474888 | 0.76 | FAAH (0.35) | FAAHMGLL | |
| SCHEMBL29363275 | 0.76 | FAAH (0.35) | FAAHMGLL | |
| SCHEMBL31482845 | 0.76 | FAAH (0.34) | FAAHMGLLTUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118416285-A | Preparation method and application of drug-loaded oil for interventional operation | 太阳雨林（厦门）生物医药有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240166650-A1 | SYNTHETIC METHODS AND INTERMEDIATES FOR PRODUCING COMPOUNDS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION (US) | 2024-05-23 | — | — | US | claimed |
| EP-4301758-A1 | SYNTHETIC METHODS AND INTERMEDIATES FOR PRODUCING COMPOUNDS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | Blueprint Medicines Corporation (US) | 2024-01-10 | — | — | EP | claimed |
| CN-111094281-B | Chemical process for preparing monolactam antibiotics and intermediates thereof | 诺华股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2022187477-A1 | SYNTHETIC METHODS AND INTERMEDIATES FOR PRODUCING COMPOUNDS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION (US) | 2022-09-09 | — | — | WO | claimed |
| US-11414411-B2 | Chemical process for manufacturing monobactam antibiotic and intermediates thereof | NOVARTIS AG (CH) | 2022-08-16 | — | — | US | claimed |
| EP-3661933-B1 | PROCESS FOR PREPARING 1-(((Z)-(1-(2-AMINOTHIAZOL-4-YL)-2-OXO-2-(((3S,4R)-2-OXO-4-((2-OXOOXAZOLIDIN-3-YL)METHYL)-1-SULFOAZETIDIN-3- YL)AMINO)ETHYLIDENE)AMINO)OXY)CYCLOPROPANE CARBOXYLIC ACID | NOVARTIS AG (CH) | 2022-03-23 | — | — | EP | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-20260118357-A1 | TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4649086-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4622959-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| CN-113166618-B | Adhesive composition and surface protective film | DIC株式会社 | 2022-08-23 | — | — | CN | disclosed |
| US-11414411-B2 | Chemical process for manufacturing monobactam antibiotic and intermediates thereof | NOVARTIS AG (CH) | 2022-08-16 | — | — | US | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
| EP-3981772-A1 | TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| EP-3661933-B1 | PROCESS FOR PREPARING 1-(((Z)-(1-(2-AMINOTHIAZOL-4-YL)-2-OXO-2-(((3S,4R)-2-OXO-4-((2-OXOOXAZOLIDIN-3-YL)METHYL)-1-SULFOAZETIDIN-3- YL)AMINO)ETHYLIDENE)AMINO)OXY)CYCLOPROPANE CARBOXYLIC ACID | NOVARTIS AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | FAAH 4265/4885MGLL 3171/4885TUBB4A 1106/4885 |
| US-11414411-B2 | Chemical process for manufacturing monobactam antibiotic and intermediates thereof | SRR, DCXR, JMJD6 | FAAH 3787/4885MGLL 1169/4885TUBB4A 3045/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | FAAH 3932/4885MGLL 2950/4885TUBB4A 1511/4885 |
| US-20240166650-A1 | SYNTHETIC METHODS AND INTERMEDIATES FOR PRODUCING COMPOUNDS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | PDGFRA, KIT, PDGFRB | FAAH 4279/4885MGLL 3563/4885TUBB4A 1111/4885 |
| US-20260118357-A1 | TETRA-FUNCTIONAL CHEMICAL PROBE AND METHOD FOR IDENTIFYING TARGET MEMBRANE PROTEIN FROM LIVING CELL OR LIVING TISSUE BY USING SAID PROBE | BTD, FABP2, FABP3 | FAAH 661/4885MGLL 1816/4885TUBB4A 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.